Kushwaha V, Kumar Sahu K
Curr Pharm Biotechnol. 2024; 26(2):186-207.
PMID: 39161136
DOI: 10.2174/0113892010331845240802073645.
Song F, Kovac V, Mohammadi B, Littau J, Scharfenberg F, Matamoros Angles A
Acta Neuropathol. 2024; 148(1):2.
PMID: 38980441
PMC: 11233397.
DOI: 10.1007/s00401-024-02763-5.
Viles J
Angew Chem Weinheim Bergstr Ger. 2024; 135(25):e202215785.
PMID: 38515735
PMC: 10952214.
DOI: 10.1002/ange.202215785.
Viles J
Angew Chem Int Ed Engl. 2023; 62(25):e202215785.
PMID: 36876912
PMC: 10953358.
DOI: 10.1002/anie.202215785.
Marques C, Gomes R, Pedron T, Batista B, Cerchiaro G
Mol Cell Biochem. 2022; 478(8):1847-1865.
PMID: 36576715
DOI: 10.1007/s11010-022-04631-w.
, inflammation and prion protein binding.
Forloni G, La Vitola P, Balducci C
Front Neurosci. 2022; 16:822420.
PMID: 36081661
PMC: 9445368.
DOI: 10.3389/fnins.2022.822420.
Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance.
Loh D, Reiter R
Molecules. 2022; 27(3).
PMID: 35163973
PMC: 8839844.
DOI: 10.3390/molecules27030705.
Prion Protein: The Molecule of Many Forms and Faces.
Kovac V, Serbec V
Int J Mol Sci. 2022; 23(3).
PMID: 35163156
PMC: 8835406.
DOI: 10.3390/ijms23031232.
Anchorless risk or released benefit? An updated view on the ADAM10-mediated shedding of the prion protein.
Mohammadi B, Song F, Matamoros-Angles A, Shafiq M, Damme M, Puig B
Cell Tissue Res. 2022; 392(1):215-234.
PMID: 35084572
PMC: 10113312.
DOI: 10.1007/s00441-022-03582-4.
Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies.
Linsenmeier L, Mohammadi B, Shafiq M, Frontzek K, Bar J, Shrivastava A
Sci Adv. 2021; 7(48):eabj1826.
PMID: 34818048
PMC: 8612689.
DOI: 10.1126/sciadv.abj1826.
Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part I. a literature review.
Dexter E, Kong Q
Expert Rev Neurother. 2021; 21(9):969-982.
PMID: 34470561
PMC: 8453080.
DOI: 10.1080/14737175.2021.1965881.
Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development.
Dexter E, Kong Q
Expert Rev Neurother. 2021; 21(9):983-991.
PMID: 34470554
PMC: 8453096.
DOI: 10.1080/14737175.2021.1965882.
Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers.
Amin L, Harris D
Nat Commun. 2021; 12(1):3451.
PMID: 34103486
PMC: 8187732.
DOI: 10.1038/s41467-021-23507-z.
Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy.
Konig A, Rosener N, Gremer L, Tusche M, Flender D, Reinartz E
J Biol Chem. 2021; 296:100499.
PMID: 33667547
PMC: 8042448.
DOI: 10.1016/j.jbc.2021.100499.
Lysozyme Fibrils Alter the Mechanism of Insulin Amyloid Aggregation.
Ziaunys M, Sakalauskas A, Sneideris T, Smirnovas V
Int J Mol Sci. 2021; 22(4).
PMID: 33579016
PMC: 7916790.
DOI: 10.3390/ijms22041775.
Disordered structure and flexible roles: using the prion protein N1 fragment for neuroprotective and regenerative therapy.
Mohammadi B, Glatzel M, Altmeppen H
Neural Regen Res. 2020; 16(7):1431-1432.
PMID: 33318441
PMC: 8284303.
DOI: 10.4103/1673-5374.301008.
Transgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER Translocation.
Mohammadi B, Linsenmeier L, Shafiq M, Puig B, Galliciotti G, Giudici C
Mol Neurobiol. 2020; 57(6):2812-2829.
PMID: 32367491
PMC: 7253391.
DOI: 10.1007/s12035-020-01917-2.
Prion protein N1 cleavage peptides stimulate microglial interaction with surrounding cells.
Carroll J, Groveman B, Williams K, MOORE R, Race B, Haigh C
Sci Rep. 2020; 10(1):6654.
PMID: 32313035
PMC: 7171115.
DOI: 10.1038/s41598-020-63472-z.
The Quest for Cellular Prion Protein Functions in the Aged and Neurodegenerating Brain.
Gavin R, Lidon L, Ferrer I, Del Rio J
Cells. 2020; 9(3).
PMID: 32131451
PMC: 7140396.
DOI: 10.3390/cells9030591.
PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.
Mengel D, Hong W, Corbett G, Liu W, DeSousa A, Solforosi L
Brain Res. 2018; 1710:125-135.
PMID: 30593771
PMC: 6431553.
DOI: 10.1016/j.brainres.2018.12.038.